Severe Eosinophilic Asthma

Disease State Hub

Q&As

EXpert Q&A

Best Practices for Managing Severe Asthma

04/19/2022

Sandhya Khurana, MD, from the University of Rochester, answers our questions about evidence-based best practices when addressing the special needs of patients with severe asthma.

04/19/2022

Research Summaries

Research Summary

Research Summary

Azithromycin Reduces Residual Exacerbations in Biologic-Treated Severe Asthma: A Single-Center Audit

09/23/2025

Anthony Calabro, MA

In patients with severe asthma who experience persistent exacerbations despite biologic therapy, azithromycin reduced both steroid- and antibiotic-requiring events and improved symptom control, according to...

09/23/2025

research summary

research summary

Exacerbations Increased After Discontinuing Long-term Use of Mepolizumab for Severe Eosinophilic Asthma

08/19/2022

While the long-term safety and efficacy of mepolizumab have been studied, gaps in the literature have remained on the clinical impact of stopping mepolizumab after long-term use. Researchers examined how...

08/19/2022

asthma

FDA Approves New Option for Severe Eosinophilic Asthma

11/15/2017

The FDA has approved a new add-on maintenance treatment option for patients with severe asthma with eosinophilic phenotype.

11/15/2017

April 2026

Current Issue

April 2026